FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953570926> ?p ?o ?g. }

• W2953570926 endingPage "CT237" @default.
• W2953570926 startingPage "CT237" @default.
• W2953570926 abstract "Abstract Background: Following infusion of tisagenlecleucel, quantitative polymerase chain reaction (qPCR) can be used to measure in vivo kinetics of CAR transgene. The utility of qPCR to inform individual pt treatment decisions and measure functional persistence is an active area of research. Objective: To determine if CAR transgene detection by qPCR can be used to inform treatment decisions. Methods: Transgene levels in blood measured by qPCR from pivotal phase II studies in pts with relapsed/refractory pediatric and young adult acute lymphoblastic leukemia (pALL; ELIANA [NCT02435849, N=75] and ENSIGN [NCT02228096, N=29]) and adult diffuse large B-cell lymphoma (DLBCL; JULIET [NCT02445248, N=93]) were used to investigate the relationship between transgene persistence and clinical response. Results: In both pALL and DLBCL, there were detectable CAR transgene levels by qPCR in both responders and nonresponders. The geometric mean maximal expansion (Cmax) was similar between responding and nonresponding DLBCL pts, while a 1.7-fold difference was observed in pALL pts. For both DLBCL and pALL, high inter-individual variability in transgene levels was noted. Similarly, higher CAR-T cell expansion from flow cytometry data pooled from responding pALL and pediatric chronic lymphocytic leukemia pts was observed vs nonresponding pts (Mueller KT, et al. Blood 2017), while the levels in DLBCL pts were comparatively lower in blood, likely due to partitioning of functional CAR-T cells to target sites including lymph nodes. The median time to maximal transgene level (Tmax) ranged from 9-10 days in DLBCL responders and nonresponders and pALL responders, while nonresponding pALL pts showed delayed expansion with median Tmax of 20 days. The median time corresponding to last quantifiable transgene level (Tlast) and the half-life estimated from the terminal slope of the cellular kinetic profile, two indicators of persistence, were higher in responding vs nonresponding pts with DLBCL and pALL. Despite this general trend, in some cases, transgene levels were not detectable at later time points in pts with continued response. Although the majority of responding pts show persistent transgene levels, some pts maintained a favorable clinical response despite a decline in transgene levels to below the level of quantification. Conclusion: In both pALL and DLBCL, CAR transgene is initially detected at high levels with high variability in both responders and nonresponders. While the majority of responding pts tend to have persistent transgene levels, some pts maintain favorable clinical responses despite a lack of quantifiable transgene. These results indicate that transgene levels in peripheral blood are not definitive to guide clinical decisions in pALL and DLBCL. Further analysis is needed to understand how CAR transgene levels relate to disease burden and duration of response. Citation Format: Rakesh Awasthi, Karen Thudium Mueller, Gregory A. Yanik, Constantine S. Tam, Susana Rives, Joseph P. McGuirk, Michael A. Pulsipher, Michael W. Boyer, Ulrich Jaeger, Andre Baruchel, Gary D. Myers, Peter Borchmann, Stephen J. Schuster, Heather Stefanski, Michael Bishop, Edward R. Waldron, Ozlem Anak, Abhijit Chakraborty, Eric Bleickardt, Stephane Wong, Lida Bubuteishvili Pacaud, Edmund K. Waller, Shannon L. Maude. Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT237." @default.
• W2953570926 created "2019-07-12" @default.
• W2953570926 creator A5006173110 @default.
• W2953570926 creator A5011386306 @default.
• W2953570926 creator A5016370299 @default.
• W2953570926 creator A5018536511 @default.
• W2953570926 creator A5020712214 @default.
• W2953570926 creator A5024123180 @default.
• W2953570926 creator A5024474361 @default.
• W2953570926 creator A5028693685 @default.
• W2953570926 creator A5034083208 @default.
• W2953570926 creator A5034517642 @default.
• W2953570926 creator A5036988600 @default.
• W2953570926 creator A5048369262 @default.
• W2953570926 creator A5052064208 @default.
• W2953570926 creator A5052541853 @default.
• W2953570926 creator A5052844124 @default.
• W2953570926 creator A5055938005 @default.
• W2953570926 creator A5064132655 @default.
• W2953570926 creator A5068525415 @default.
• W2953570926 creator A5080630441 @default.
• W2953570926 creator A5083591281 @default.
• W2953570926 creator A5084871192 @default.
• W2953570926 creator A5087074127 @default.
• W2953570926 creator A5089893290 @default.
• W2953570926 date "2019-07-01" @default.
• W2953570926 modified "2023-09-27" @default.
• W2953570926 title "Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel" @default.
• W2953570926 doi "https://doi.org/10.1158/1538-7445.am2019-ct237" @default.
• W2953570926 hasPublicationYear "2019" @default.
• W2953570926 type Work @default.
• W2953570926 sameAs 2953570926 @default.
• W2953570926 citedByCount "0" @default.
• W2953570926 crossrefType "journal-article" @default.
• W2953570926 hasAuthorship W2953570926A5006173110 @default.
• W2953570926 hasAuthorship W2953570926A5011386306 @default.
• W2953570926 hasAuthorship W2953570926A5016370299 @default.
• W2953570926 hasAuthorship W2953570926A5018536511 @default.
• W2953570926 hasAuthorship W2953570926A5020712214 @default.
• W2953570926 hasAuthorship W2953570926A5024123180 @default.
• W2953570926 hasAuthorship W2953570926A5024474361 @default.
• W2953570926 hasAuthorship W2953570926A5028693685 @default.
• W2953570926 hasAuthorship W2953570926A5034083208 @default.
• W2953570926 hasAuthorship W2953570926A5034517642 @default.
• W2953570926 hasAuthorship W2953570926A5036988600 @default.
• W2953570926 hasAuthorship W2953570926A5048369262 @default.
• W2953570926 hasAuthorship W2953570926A5052064208 @default.
• W2953570926 hasAuthorship W2953570926A5052541853 @default.
• W2953570926 hasAuthorship W2953570926A5052844124 @default.
• W2953570926 hasAuthorship W2953570926A5055938005 @default.
• W2953570926 hasAuthorship W2953570926A5064132655 @default.
• W2953570926 hasAuthorship W2953570926A5068525415 @default.
• W2953570926 hasAuthorship W2953570926A5080630441 @default.
• W2953570926 hasAuthorship W2953570926A5083591281 @default.
• W2953570926 hasAuthorship W2953570926A5084871192 @default.
• W2953570926 hasAuthorship W2953570926A5087074127 @default.
• W2953570926 hasAuthorship W2953570926A5089893290 @default.
• W2953570926 hasConcept C102230213 @default.
• W2953570926 hasConcept C104317684 @default.
• W2953570926 hasConcept C112705442 @default.
• W2953570926 hasConcept C126322002 @default.
• W2953570926 hasConcept C143998085 @default.
• W2953570926 hasConcept C150903083 @default.
• W2953570926 hasConcept C203014093 @default.
• W2953570926 hasConcept C207001950 @default.
• W2953570926 hasConcept C22979827 @default.
• W2953570926 hasConcept C2779338263 @default.
• W2953570926 hasConcept C553184892 @default.
• W2953570926 hasConcept C55493867 @default.
• W2953570926 hasConcept C71924100 @default.
• W2953570926 hasConcept C86803240 @default.
• W2953570926 hasConceptScore W2953570926C102230213 @default.
• W2953570926 hasConceptScore W2953570926C104317684 @default.
• W2953570926 hasConceptScore W2953570926C112705442 @default.
• W2953570926 hasConceptScore W2953570926C126322002 @default.
• W2953570926 hasConceptScore W2953570926C143998085 @default.
• W2953570926 hasConceptScore W2953570926C150903083 @default.
• W2953570926 hasConceptScore W2953570926C203014093 @default.
• W2953570926 hasConceptScore W2953570926C207001950 @default.
• W2953570926 hasConceptScore W2953570926C22979827 @default.
• W2953570926 hasConceptScore W2953570926C2779338263 @default.
• W2953570926 hasConceptScore W2953570926C553184892 @default.
• W2953570926 hasConceptScore W2953570926C55493867 @default.
• W2953570926 hasConceptScore W2953570926C71924100 @default.
• W2953570926 hasConceptScore W2953570926C86803240 @default.
• W2953570926 hasIssue "13_Supplement" @default.
• W2953570926 hasLocation W29535709261 @default.
• W2953570926 hasOpenAccess W2953570926 @default.
• W2953570926 hasPrimaryLocation W29535709261 @default.
• W2953570926 hasRelatedWork W1985146449 @default.
• W2953570926 hasRelatedWork W200416378 @default.
• W2953570926 hasRelatedWork W2026429540 @default.
• W2953570926 hasRelatedWork W2065090916 @default.
• W2953570926 hasRelatedWork W2091520566 @default.
• W2953570926 hasRelatedWork W2388612886 @default.
• W2953570926 hasRelatedWork W2406142643 @default.
• W2953570926 hasRelatedWork W2414278488 @default.
• W2953570926 hasRelatedWork W2495730350 @default.

• next